OGXI OncoGenex Pharmaceuticals Inc. featured news, full reports, and detailed charts
OncoGenex Pharmaceuticals Inc. (OGXI) Wrap Up:
Sonus Pharmaceuticals is developing novel small molecule drugs for the treatment of patients with cancer. Our objective is to identify opportunities where there is the possibility for major improvements in patient treatments and where we believe we can mitigate development risk. We currently have one drug in clinical development and two earlier stage programs. Our plan is to continue to develop our internal pipeline of clinical compound opportunities and to evaluate possible strategic alternatives, including in-licensing, out-licensing and merger and acquisition opportunities, as a means of achieving our business strategies and enhancing stockholder value. In the fourth quarter of 2007 we engaged Ferghana Partners Inc., an international provider of independent financial advisory services to firms in the biotechnology, pharmaceuticals, diagnostics and specialty chemicals industries, to assist us with these strategic alternatives. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0001047469-08-002810.html#FIS_BUSINESS"OncoGenex Pharmaceuticals, Inc. (OGXI:NASDAQ)
Snapshot of OncoGenex Pharmaceuticals, Inc. (OGXI)
|
OPEN
$32.00
|
PREVIOUS CLOSE
$32.14
|
|
|
DAY HIGH
$32.77
|
DAY LOW
$31.06
|
|
|
52 WEEK HIGH
08/31/09 - $42.99
|
52 WEEK LOW
11/26/08 - $2.08
|
|
|
MARKET CAP
195.1M
|
AVERAGE VOLUME 3 mo
69.5K
|
|
|
DILUTED EPS TTM
$-2.65
|
SHARES OUTSTANDING
6.0M
|
|
|
OGXI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
OGXI Top Compensated Officers
Executives, Board Directors
Key developments for OncoGenex Pharmaceuticals, Inc. (OGXI)
OncoGenex Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, loss for the period before taxes and extraordinary gain was $2,369,000 against $2,366,000 a year ago. Income before extraordinary gain was $2,385,000 against loss before extraordinary gain of $149,000 a year ago. Net income was $2,385,000 against net income of $4,577,000 a year ago. Income attributable to common shareholders was $2,385,000 or $0.40 per basic and diluted share against loss attributable to common shareholders of $4,160,000 or $2.02 per basic and diluted share a year ago. For the nine months, loss for the period before taxes and extraordinary gain was $9,345,000 against $5,776,000 a year ago. Income before extraordinary gain was $3,676,000 against loss before extraordinary gain of $50,666,000 a year ago. Net income was $9,357,000 against net loss of $752,000 a year ago. Income attributable to common shareholders was $9,357,000 or $1.65 per basic and diluted share against income attributable to common shareholders of $1,221,000 or $1.59 per basic and diluted share a year ago. Cash used in operating activities was $9,236,000 against $7,406,000 a year ago. Capital expenditure on purchase of property and equipment was $15,000 against $4,000 a year ago.
OncoGenex Pharmaceuticals, Inc., Q3 2009 Earnings Call, Nov-05 2009
OncoGenex Pharmaceuticals Inc. announced that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with docetaxel for treatment of progressive metastatic prostate cancer following docetaxel. Fast Track Designation is granted to products that may provide a significant improvement in the safety or effectiveness of the treatment for a serious or life-threatening disease. Based on this designation, the FDA will take actions as appropriate to expedite the development and review of OGX-011 for approval. These actions include scheduled meetings to obtain FDA input into development plans, and the option of submitting a New Drug Application in sections rather than all components simultaneously. The request for Fast Track designation was based on data from the randomized, Phase 2 study (Study OGX-011-03) that suggested OGX-011 in combination with first-line docetaxel treatment may improve survival in patients with castrate resistant prostate cancer (CRPC). The median overall survival in patients with CRPC who were treated with OGX-011 plus first-line docetaxel was 23.8 months (95% Confidence Interval (CI) from 16.2 to infinity) compared to 16.9 months (95% CI from 12.8 to 25.8) for patients treated with docetaxel alone with a hazard ratio of 0.61 (95% CI from 0.36 to 1.02).
OGXI Competitors
| Company | Last | Change | |
| No competitor information is available for OGXI. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | OGXI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 17.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
OGXI |
||
OGXI transactions
| Type Date |
Target |
|
Private Placement
July 20, 2009 |
-- |
More Recent News About OncoGenex Pharmaceuticals Inc.
More news for OGXI
OncoGenex gets FDA ‘fast track’ designation for prostate cancer drug
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for ONCOGENEX PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ONCOGENEX PHARMACEUTICALS, INC. 6-Oct-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information ...Click here to read the whole Article (external link)
Four High-Flying Pharmaceutical Companies
Since the stock market bottomed in March, one of the fastest-climbing sectors has been the pharmaceuticals. These issues can be explosive. Pending approval from the necessary regulatory bodies, pharmaceutical developers can see their shares double or triple in value - or even better. IN PICTURES: Digging Out Of Debt In 8 StepsThe following issues are among the best-performing stocks year to date in the Russell 3000, up anywhere from 400% to 2000% in that period. Vanda Pharmaceuticals (Nasdaq: VNDA) stock has climbed nearly 2000% since the New Year began, most of it directly after receiving approval from the FDA for its patented schizophrenia treatment. Since then, the stock has held up strongly. Just last week Vanda announced it was teaming up with pharmaceutical giant Novartis AG (NYSE: NVSU.S.Canada. North America is $14 billion. Swine Flu VaccineBioCryst Pharmaceuticals (Nasdaq: BCRX) is another fast-moving biotech with a number of drugs in its portfolio, each at a different phase of the FDA approval process. The company develops treatments that block enzymes involved in cancer, viral infections and auto-immune diseases. ...Click here to read the whole Article (external link)
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
BOTHELL, WA and VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI - News) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon to provide a business update and discuss the third quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-466-4520 (U.S. & Canada) or 719-457-2729 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.About OncoGenex PharmaceuticalsOncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit th...Click here to read the whole Article (external link)
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
Show all filings for ONCOGENEX PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ONCOGENEX PHARMACEUTICALS, INC. 5-Nov-2009Results of Operations and Financial Condition, Financial Statemen Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informa...Click here to read the whole Article (external link)
OncoGenex Reports Third Quarter 2009 Financial Results
Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI - News) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.Research and development expenses for the third quarter of 2009 decreased to $1.5 million from $1.6 million in 2008, due mainly to lower costs associated with OGX-427. For the nine months ended September 30, 2009 research and development expenses increased to $6.8 million from $3.6 million in 2008. The increase was primarily due to OGX-011 and OGX-427 manufacturing-related costs incurred in the first nine months of 2009, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first nine months of 2008 was a Scientific Research and Development (SRED) claim, which offset R&D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company a...Click here to read the whole Article (external link)
Piper Jaffray Senior Research Analyst Sees M&A Activity As Brisk As Foreign Companies Seek US Specialty Pharmaceutical Distribution Networks
67 WALL STREET, New York - November 13, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); N...Click here to read the whole Article (external link)
ONCOGENEX PHARMACEUTICALS, INC. Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue - - - - Cost of Revenue - - - - Gross Profit - - - - Operating ExpensesResearch Development1,513 3,588 1,694 4,198 Selling General and Administrative885 1,003 782 1,050 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(2,398)(4,591)(2,476)(5,248)Income from Continuing OperationsTotal Other Income/Expenses Net(211)34 57 333 Earnings Before Interest And Taxes(2,609)(4,557)(2,419)(4,915)Interest Expense - - - - Income Before Tax(2,609)(4,557)(2,419)(4,915)Income Tax Expense(8)6 (10)41 Minority Interest - - - - Net Income From Continuing Ops16,329 (4,563)(2,409)(4,956)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - ...Click here to read the whole Article (external link)